Abpro Corporation (ABP)
0.94
-0.02 (-2.08%)
At close: Feb 04, 2025, 3:59 PM
0.98
4.24%
After-hours Feb 04, 2025, 06:53 PM EST
Company Description
Abpro Holdings, Inc., a biotechnology company, engages in developing antibody therapeutics for patients with immuno-oncology, ophthalmology, and autoimmunity issues.
Its platform DiversImmune addresses a bottleneck in the antibody therapeutics industry.
Its lead product candidates include ABP-100 for the treatment of breast, gastric, and colorectal cancers; and ABP-201 for the treatment of vascular diseases of the eye.
The company has a strategic partnership with Abpro Bio Co. Ltd and NJCTTQ.
The company was formerly known as Abpro Corporation and changed its name to Abpro Holdings, Inc. in November 2024.
Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.
Abpro Corporation
| Country | United States |
| IPO Date | Mar 9, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Jin Wook Suk |
Contact Details
Address: 68 Cummings Park Drive Woburn, Massachusetts United States | |
| Website | https://abpro.com |
Stock Details
| Ticker Symbol | n/a |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | n/a |
| ISIN Number | n/a |
| Employer ID | - |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| Ian Chan | Co-Founder, Chief Executive Officer & Director |
| Jin Wook Suk | CO-Chief Executive Officer & Chairman of the Board |
| Dr. Robert J. Markelewicz Jr., M.D. | Chief Medical Officer |
| Eugene Y. Chan M.D. | Co-Founder |